Text Size

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2006 by Samsung Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00539786
First received: October 3, 2007
Last updated: October 4, 2007
Last verified: March 2006
History of Changes
  Purpose

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.


Condition Intervention
Gastroesophageal Reflux Disease
 Drug: Proton pump inhibitor (rabeprazole)

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms

Resource links provided by NLM:

MedlinePlus related topics: GERD
U.S. FDA Resources

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • Symptom responders after PPI trials

Study Start Date: March 2006
Intervention Details:
    Drug: Proton pump inhibitor (rabeprazole)
    Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients with extraesophageal manifestation symptoms of GERD

Exclusion Criteria:

  • laryngeal, pharyngeal, liver, lung, renal, or hematological disorders
  • a history of gastrointestinal surgery, and a history of connective tissue disorders.
  • patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00539786

Contacts
Contact: Tae ggon Kim +82-2-3410-2975 tggo.kim@samsung.com

Locations
Korea, Republic of
Samsung Medical Center, Sungkyunkwan University School of Medicine Recruiting
Seoul, Gangnam-gu, Korea, Republic of, 135-710
Contact: Poong Lyul Rhee, M.D., Ph.D     +82-2-3410-3409     plrhee@skku.edu    
Principal Investigator: Poong-Lyul Rhee, M.D., Ph.D.            
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Poong-Lyul Rhee, MD. Ph.D Samsung Medical Center, Sungkyunkwan University School of Medicine
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00539786     History of Changes
Other Study ID Numbers: 2006-03-071
Study First Received: October 3, 2007
Last Updated: October 4, 2007
Health Authority: Korea: Food and Drug Administration

Keywords provided by Samsung Medical Center:
Patients with extraesophageal manifestation of gastroesophageal reflux dsiease

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Rabeprazole
 Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013